AzTrials
AzTrials

Urethral StricturePhase 1LBMGNCT03061344

Liquid Buccal Mucosa Graft Urethroplasty

A Phase 1 study testing DVIU treated with liquid buccal mucosal graft in people with Urethral Stricture, run by State University of New York - Upstate Medical University at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Study Objectives The current definitive treatment options for urethral stricture disease include endoscopic urethrotomy known as Direct Vision Internal Urethrotomy (DVIU) or open reconstruction known as urethroplasty (1-6). Read more about this study

Who is it for?
Ages 18 years and older, men only
Conditions the study is for
Urethral Stricture
What is being tested?
DVIU treated with liquid buccal mucosal graft
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteUnited States
Study dates
Feb 2017to Oct 2021
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male >18 years of age
  • bulbar urethral stricture
  • bladder neck contracture

Who cannot join

  • <18 years old
  • developmental delay
  • incarcerated individuals,
  • history of prior urethroplasty
  • history of cerebrovascular diseases (prior stroke, MI)
  • history of deep vein thrombosis
Show all 18Show fewer
  • history of pulmonary embolism
  • history of clotting disorders
  • factor 5 Leiden
  • antiphospholipid antibody syndrome
  • prothrombin gene mutation
  • protein S deficiency
  • protein C deficiency
  • dysfibrinogenemia
  • polycythemia vera
  • essential thrombocytosis
  • untreated malignancy
  • hypercoagulable state

Trial locations and contacts

1 site in 1 country.

Dmitriy Nikolavsky, MD contact

315-464-1500

nikolavd@upstate.edu

United States1 site
  • SUNY Upstate Medical University

    Syracuse, New York, 13210

Other trials in United States

About this study

Official title: Endoscopic Buccal Mucosal Graft Urethroplasty or Bladder Neck Reconstruction

Study Objectives The current definitive treatment options for urethral stricture disease include endoscopic urethrotomy known as Direct Vision Internal Urethrotomy (DVIU) or open reconstruction known as urethroplasty (1-6). The purpose of this study is to determine feasibility of endoscopic-only repair of urethral stricture or bladder neck contracture using a combination of existing surgical techniques of internal urethrotomy (or bladder neck incision) augmented by buccal mucosal graft.

Read the detailed description

Background and Rationale There are two definitive treatment options for urethral strictures: DVIU and open urethroplasty. DVIU is an endoscopic procedure considered to be minimally invasive, but also with a high failure rate of 60-92%. The repeated DVIUs are reported to have even higher failure rates. On the other hand, open urethroplasty, considered a gold standard for reconstruction, is invasive, requires incision of the perineum or urethra, leaves a life-long scar, and has long term success rates of 74-95%. The details of DVIU and open urethroplasty are discussed below.

DVIU involves passing a cystoscope into the urethra to the level of stricture and incising the stricture longitudinally to create a wide passage to the level of normal urethra on the proximal side. The hope is to cut through the scar to the level of healthy underlying tissue and in the process of healing to populate the cut surface with healthy urethral epithelium (or at least to stabilize the scar in open configuration). In most cases, the scarring recurs faster than epithelization and most strictures recur after DVIU within 7-8 months. Studies show the strictures after traditional repeat DVIU are longer and require more involved reconstruction than strictures in patients without prior instrumentation.

Open urethroplasty for urethral strictures or bladder neck contractures usually involves longitudinal incision of the urethra (from outside in) and augmentation of the incised part with a strip of harvested Buccal Mucosal Graft (BMG). The goal of the operation is to create a wide urethral lumen for the patient to be able to pass urine without obstruction.

The first step of the procedure for DVIU and open reconstruction are nearly the same: a longitudinal incision of the scarred portion of the urethra. The difference is in the second part: covering the defect with buccal mucosal graft as in open urethroplasty vs leaving the incision uncovered and exposed to passage of urine.

Investigators of this study hereby propose to combine the minimally invasive technique of the DVIU with the technique of augmenting the incised stricture (or bladder neck contracture) using buccal mucosal graft placed endoscopically by means of application of liquid suspended graft. A similar, but more invasive technique was reported by Seith et al in 2012 performed in 12 patients with the exception of need for small open perineal incision for graft fixation. A purely endoscopic skin graft placement into urethra was reported by Naude in 1998 in 53 patients with 95% success rate at 2 years follow up. While he has not made actual incisions, his approach required percutaneous perineal needle placement for graft delivery and a specialized device for graft delivery and graft fixation. The procedure proposed for current trial is purely endoscopic with buccal graft placement and fixation augmented by fibrin glue. This type of fibrin glue sealant is readily available and widely used in General Surgery, Plastic Surgery and in Urology specifically for urethral reconstruction). This will allow for significantly less invasive procedure, shorter procedure time, absence of traditional perineal incision or needle puncture, and earlier return home (same day vs 1-3 days), earlier catheter removal (5-7 days vs 21 days) and earlier return to regular activities (1 week vs 6 weeks).

Overall, the aim is to improve the outcomes of traditional endoscopic procedure while eliminating morbidity of the open reconstruction with added benefits of earlier convalescence and health care savings from decreased surgical morbidity and shortened hospital stay.

Being tested
DVIU treated with liquid buccal mucosal graft
Medical subject headings
Urethral Stricture

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DVIU treated with liquid buccal mucosal graftBiological

    DVIU treated with liquid buccal mucosal graft; internal urethrotomy for urethral stricture followed by injection of morcellated buccal mucosal graft mixed with fibrin glue (Tisseel, Baxter)

Study groups in NCT03061344
Study groupRoleWhat they receive
liquid buccal mucosa graftExperimentalDVIU treated with liquid buccal mucosal graft; endoscopic injection of morcellated buccal mucosal graft mixed with fibrin glue
Receives: Biological: DVIU treated with liquid buccal mucosal graft

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Voiding Surgical Outcomes: Stricture Recurrence

    The ultimate outcome of this procedure is number of patients successfully treated without need for re-intervention (such as need for urethral dilation, endoscopic manipulation or open reconstruction). Recurrence of stricture will be reported as number of events. To detect stricture recurrence, patients will be monitored with: peak urine flow (milliliters per second) and post-void residuals (milliliters) and will be assessed post- operatively at every visit up to three years Flexible cystoscopy will be offered to patients at one year follow up or at any time point if there is suspicion of stricture recurrence based on patients complaints (reported as number of recurrences).

    Measured: 3 years

Secondary outcomes (3)
  1. Immediate Perioperative Outcomes

    This is a composite outcome measure consisting of the following measures: duration of surgery (time in minutes), immediate postoperative complications: bleeding requiring blood transfusion (units of transfused blood), cerebrovascular complications reported as number of events (stroke, myocardial infarctions, pulmonary emboli) , problems with anesthesia (inability to extubate, need to re-intubate reported as number of each events), allergic reactions including anaphylaxis (number) and, duration of hospital stay (days).

    Measured: Day of surgery

  2. Short-term Postoperative Outcomes

    This is a composite outcome measure consisting of the following measures: Urinary Tract Infection (number of infections requiring treatment), Sepsis (number of events), unscheduled ER visits (number), readmissions for hospital stay (number of events).

    Measured: Up to 90 days

  3. Patient Satisfaction

    Global Response Assessment questionnaire will be given to patients at every visit to assess overall satisfaction with the procedure.

    Measured: Post-operative up to 3 years follow up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Feb 2017
  2. Study startFeb 2017 (estimated)
  3. Primary completionOct 2019 (estimated)
  4. Study completionOct 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03061344
Sponsor's protocol ID
SUNYUpstateMU
Acronym
LBMG
Status last verified
Feb 2017
First submitted
19 Aug 2016
Last updated
23 Feb 2017
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing DVIU treated with liquid buccal mucosal graft in people with Urethral Stricture, run by State University of New York - Upstate Medical University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 23 Feb 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Dmitriy Nikolavsky, MD (315-464-1500, nikolavd@upstate.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Voiding Surgical Outcomes: Stricture Recurrence (time frame: 3 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in